Secondary Logo

Journal Logo

February-March 2009 - Volume 32 - Issue 2
pp: 101-205


Vaccination With a Recombinant Protein Encoding the Tumor-specific Antigen NY-ESO-1 Elicits an A2/157-165-specific CTL Repertoire Structurally Distinct and of Reduced Tumor Reactivity Than That Elicited by Spontaneous Immune Responses to NY-ESO-1-expressing Tumors

Bioley, Gilles; Guillaume, Philippe; Luescher, Immanuel; More

Journal of Immunotherapy. 32(2):161-168, February-March 2009.

Manufacturing Validation of Biologically Functional T Cells Targeted to CD19 Antigen for Autologous Adoptive Cell Therapy

Hollyman, Daniel; Stefanski, Jolanta; Przybylowski, Mark; More

Journal of Immunotherapy. 32(2):169-180, February-March 2009.

Retrospective Analysis of the Safety and Efficacy of Interleukin-2 After Prior VEGF-targeted Therapy in Patients With Advanced Renal Cell Carcinoma

Cho, Daniel C.; Puzanov, Igor; Regan, Meredith M.; More

Journal of Immunotherapy. 32(2):181-185, February-March 2009.

Treatment of Malignant Pleural Effusion With the Trifunctional Antibody Catumaxomab (Removab) (Anti-EpCAM×Anti-CD3): Results of a Phase 1/2 Study

Sebastian, Martin; Kiewe, Philipp; Schuette, Wolfgang; More

Journal of Immunotherapy. 32(2):195-202, February-March 2009.